直 Japanese PDF Font
  • 구성원
  • 업무분야
  • 소식 및 자료
  • 사무소
  • Firm
  • 채용공고
Finnegan
    • AI + Finnegan
    • Appeals, Issues, and Legal Strategy
    • Diligence, Licensing, and Opinions
    • Global IP Enforcement, Litigation, and Trials
    • Patent Office Invalidation Proceedings
    • Prosecution and Portfolio Management
    • Trademark and Brand Management
    • AI, Electronics, and Information Technology
    • Chemicals, Industrials, and Materials
    • Communications
    • Consumer Goods and Services
    • Energy
    • Hospitality, Gaming, and Leisure
    • 생명과학
    • Transportation and Logistics
  • 업무사례

특허 소송 및 재판

About

Strong cases built on complete comprehension of the law and your business goals

When cases involve highly technical or science-based issues, it is essential that your legal team understand the subject matter of the dispute as well as the case law and procedural nuances specific to intellectual property law. Finnegan’s singular focus on IP gives clients a distinct advantage, because unlike other types of litigation, patent cases are often resolved before a trial ever begins. Claim construction, prior art searches, evaluations of a patent’s strengths and weaknesses, invalidity challenges, reexamination alternatives, building a damages strategy, identification of experts—these are just a few of the issues that can predetermine the outcome of a patent litigation.

We work with clients to help align litigation strategy with business goals, which might mean settling on reasonable terms as early as possible, or alternatively, sending a message to industry competitors through aggressive enforcement or defensive strategies. In our experience, a good settlement can often result in advantageous business solutions. As circumstances warrant, we assemble a skilled team from our deep bench to assist with crafting settlements before, during, and after trial so the litigation team can remain focused on the trial. Historically, some of our most significant achievements for clients have been attained through tactics that allowed them to meet their business and financial goals without the risks attendant to having a judge, jury, arbitration panel, administrative board, or appellate panel decide their future.

If your case goes to trial, the right team makes all the difference

When trial is the best or only option, Finnegan brings the right mix of technical expertise and trial and appellate experience. For 60 years, we have successfully litigated hundreds of cases involving the most technologically advanced and complex patents and argued the decisions on appeal by intentionally setting the trial record and fully preserving issues.

We have patent professionals who hold Ph.D.’s in fields ranging from neurobiology to electrical engineering, and more than a hundred hold master’s degrees. Before and during trial, our knowledge and intellectual firepower are applied to make the most intricate issues easily understood and to undercut the opposing side’s arguments. We build and present cases that are accurate, understandable, and persuasive.

Insight into every forum

We know the forums for IP disputes because we have successfully argued cases in the top IP venues for jurisdictions we serve, including in German regional civil courts, U.S. district courts, the UK Intellectual Property Enterprise Court, the UK High Court, the German Federal Patent Court (FPC), the U.S. International Trade Commission (ITC), the U.S. Court of Federal Claims, the German Federal Court of Justice (FCJ), the UK Court of Appeal, the U.S. Court of Appeals for the Federal Circuit, and the U.S. Supreme Court. We have also worked at these courts and agencies, and many of our professionals have backgrounds as judicial law clerks in trial and appellate courts. Across our eleven global offices, we diligently helped clients prepare for the June 2023 opening of the European Union’s Unified Patent Court (UPC), and we were among the first firms to file an action in the UPC.

Everyone in this practice

업무사례

VDPP, LLC v. Volkswagen Group of America, Inc.

Secured dismissal with prejudice by establishing that plaintiff failed to plead compliance with the patent-marking requirements of 35 U.S.C. § 287. Successfully defended the judgment on appeal, where the Federal Circuit issued a precedential decision affirming the dismissal and attorney-fee award, strengthening precedent on patent marking and appellate jurisdiction. 

4:23-cv-02961, S.D. Tex., Judge Rosenthal
24-2226, Fed. Cir., Judges Lourie, Cunningham, Moore

In the Matter of Certain Semiconductor Devices and Products Containing the Same

Achieved a comprehensive victory for respondent Innoscience, a global leader in gallium nitride (GaN) power devices, in a high-profile patent dispute before the U.S. International Trade Commission (ITC). The ITC’s Final Determination confirms that Innoscience avoided all patent claims asserted by Infineon.

337‑TA‑1414, ITC, Judge Moore

WirelessWerx IP, LLC v. Audi of America, Inc.

Persuaded the court that asserted claims directed to an alleged form of geofencing technology were ineligible under 35 U.S.C. § 101. The court found the patent invalid and dismissed the case against client Audi with prejudice in the first instance.

4:25-cv-11147, E.D. Mich., Judge Behm

Represented a global pharmaceutical company against a generic company on a patent covering an injectable painkilling medicine for short-term pain relief*

Represented a global pharmaceutical company against a generic company on a patent covering an injectable painkilling medicine for short-term pain relief.

Promptu Systems Corporation v. Comcast Corporation

Obtained a $240 million jury verdict for client Promptu in a patent infringement lawsuit against Comcast. The jury found that Comcast willfully infringed Promptu’s patents covering voice recognition technology for TV.

2:16-cv-06516, E.D. Pa., Judge Sanchez
22-1939, Fed. Cir., Judges Prost, Moore, Taranto

Advised a global healthcare company in anticipated court proceedings seeking declarations of non-infringement related to its influenza vaccines*

Advised a global healthcare company in anticipated court proceedings seeking declarations of non-infringement related to its influenza vaccines.

More

Insights

Conference

IAM Live: Auto IP Europe 2026

October 22, 2026

Munich

Seminar

Future IP UK

October 21, 2026

London

Hybrid Conference

Intellectual Property Law Institute 2026 – California

October 19-20, 2026

San Francisco

Conference

LES 2026 Annual Meeting

October 18-21, 2026

San Diego

Hybrid Seminar

Annual Intellectual Property Law Section Fall Seminar

October 16, 2026

Alexandria

Webinar

2026 Inventive Step in Europe and the US: Comparing the UPC, EPO and National Approaches

October 14, 2026

Webinar

More

Upcoming Events

Conference

2027 ABA-IPL Section Annual Meeting – IPLSPRING

April 14-15, 2027

Arlington

Conference

Patent Litigation Europe 2027

January 18-20, 2027

Amsterdam

Conference

IP Life Sciences Forum 2026

December 13-15, 2026

Coral Gables

Conference

IPBC Asia 2026

November 17-19, 2026

Tokyo

Conference

NAPABA Convention 2026

November 12-14, 2026

Los Angeles

Conference

IAM Live: Trade Secret Strategy USA

November 10, 2026

San Jose

More

뉴스

Award/Ranking

Finnegan Named an IP Litigation Powerhouse in BTI Litigation Outlook 2027

September 24, 2026

Commentary

Bloomberg Law Q&A with Finnegan IP Lawyer Christian Hurt

September 11, 2026

Award/Ranking

Finnegan Wins “Hatch-Waxman Litigation Firm of the Year – Branded” and David Weingarten Wins “Patent Strategy Attorney of the Year (South)” at the LMG Life Sciences Americas Awards

September 11, 2026

Commentary

Finnegan Joins Growing Wave of Firms Moving into Texas

September 4, 2026

Commentary

Finnegan Enters Texas Market with Former USPTO Atty

September 2, 2026

Media Mention

Finnegan Named a Finalist in Three Categories in Law.com’s  D.C. Legal Awards 

August 24, 2026

More

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • 개인정보처리방침
  • 면책공고
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP